LENZ Therapeutics, Inc.
NASDAQ Global SelectTotal Valuation
LENZ Therapeutics, Inc. carries a market capitalization of 219.79M, placing it among publicly traded companies globally. Its enterprise value stands at 14.60M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 219.79M |
| Enterprise Value | 14.60M |
Share Statistics
LENZ Therapeutics, Inc. currently has 31.35M shares outstanding.
| Shares Outstanding | 31.35M |
| Owned by Insiders (%) | N/A |
| Owned by Institutions (%) | N/A |
Valuation Ratios
The price-to-sales ratio is 12.97, and the price-to-book ratio stands at -1.01.
| PE Ratio | N/A |
| PS Ratio | 12.97 |
| PB Ratio | -1.01 |
| P/TBV Ratio | 1.10 |
| P/FCF Ratio | -3.17 |
| P/OCF Ratio | -3.14 |
Enterprise Valuation
| EV / Sales | 0.70 |
| EV / EBITDA | N/A |
| EV / EBIT | N/A |
| EV / FCF | N/A |
Financial Position
LENZ Therapeutics, Inc. maintains a current ratio of 10.40, meaning it holds 10.4x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 10.40 |
| Quick Ratio | 10.03 |
| Debt / Equity | 0.27 |
| Debt / EBITDA | -0.01 |
| Interest Coverage | N/A |
Financial Efficiency
| Return on Equity (ROE) | N/A |
| Return on Assets (ROA) | -46.01 |
| Return on Invested Capital (ROIC) | N/A |
| Return on Capital Employed (ROCE) | N/A |
| Revenue Per Employee | N/A |
| Employee Count | N/A |
| Inventory Turnover | 0.62 |
Taxes
| Income Tax | 502,000.00 |
| Effective Tax Rate | N/A |
Stock Price Statistics
LENZ Therapeutics, Inc.'s stock has declined approximately -76.4528% over the past 52 weeks. The 50-day moving average sits at 8.87, while the 200-day moving average is 21.97.
| Beta (5Y) | N/A |
| 52-Week Price Change | -76.4528% |
| 50-Day Moving Average | 8.87 |
| 200-Day Moving Average | 21.97 |
| Average Volume (20 Days) | N/A |
Income Statement
Over the trailing twelve months, LENZ Therapeutics, Inc. generated 20.99M in revenue and converted that into -109.00M in net income, yielding earnings per share of -3.66. EBITDA reached -117.98M, while operating income came in at -118.34M.
| Revenue | 20.99M |
| Gross Profit | 825,000.00 |
| Operating Income | -118.34M |
| Pretax Income | -108.49M |
| Net Income | -109.00M |
| EBITDA | -117.98M |
| EBIT | -118.34M |
| Earnings Per Share (EPS) | -3.66 |
Balance Sheet
LENZ Therapeutics, Inc. holds 258.39M in cash and equivalents against 673,000.00 in total debt, resulting in a net debt position of -24.77M. Total book value stands at -268.63M, with working capital of 242.56M providing operational flexibility.
| Cash & Cash Equivalents | 258.39M |
| Total Debt | 673,000.00 |
| Net Debt | -24.77M |
| Equity (Book Value) | -268.63M |
| Book Value Per Share | -9.03 |
| Working Capital | 242.56M |
Cash Flow
LENZ Therapeutics, Inc. produced -86.70M in operating cash flow over the past twelve months. After subtracting -735,000.00 in capital expenditures, free cash flow totaled -87.44M - equivalent to -2.94 per share.
| Operating Cash Flow | -86.70M |
| Capital Expenditures | -735,000.00 |
| Free Cash Flow | -87.44M |
| FCF Per Share | -2.94 |
Margins
LENZ Therapeutics, Inc. operates with a gross margin of 94.87, reflecting its pricing power and cost economics. The operating margin of -563.83 and net profit margin of -519.30 provide insight into operational efficiency.
| Gross Margin | 94.87 |
| Operating Margin | -563.83 |
| Pretax Margin | -516.91 |
| Profit Margin | -519.30 |
| EBITDA Margin | -562.10 |
Dividends & Yields
| Dividend Per Share | N/A |
| Dividend Yield | N/A |
| Payout Ratio | N/A |
| Shareholder Yield | -54.98 |
| FCF Yield | -31.57 |
Stock Splits
LENZ Therapeutics, Inc.'s most recent stock split took place on March 22, 2024 with a 7:1 split ratio.
| Last Split Date | 3/22/2024 |
| Split Ratio | 7:1 |
Scores
LENZ Therapeutics, Inc. posts an Altman Z-Score of 4.61, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.
| Altman Z-Score | 4.61 |